Read time: 4 minutes
Recurrent urinary tract infections (UTIs) are a frequent and disruptive issue in pediatric care, particularly in children with structural or functional urological vulnerabilities. While often managed with low-dose antibiotic prophylaxis, this approach carries long-term concerns: altered microbiota composition, antimicrobial resistance, and downstream immune or metabolic consequences.
Emerging evidence suggests that targeted probiotics may offer a microbiome-sparing alternative. By supporting colonization resistance and mucosal immunity, certain Lactobacillus strains may help reduce infection risk, particularly in children where chronic antibiotic use is neither desirable nor sustainable.
A 2024 randomized controlled trial (PMC11205481) provides new insight into this possibility, exploring whether daily supplementation with a dual-strain probiotic can reduce UTI recurrence in children with established risk factors.
This double-blind, placebo-controlled trial enrolled 54 children aged 3–18 with either recurrent UTIs or at least one episode of pyelonephritis plus an additional risk factor (e.g., vesicoureteral reflux, bladder dysfunction, or a neurogenic bladder). Participants were randomized to receive either a daily probiotic or placebo for 90 days, followed by a six-month observation period.
The intervention included two well-characterized strains: Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1. Both are known for their ability to inhibit uropathogen adherence, produce antimicrobial metabolites, and support local mucosal immunity. Importantly, the placebo was matched in taste and appearance, and adherence was closely monitored.
While the study was not powered to detect small differences, the results offer encouraging trends. Children in the probiotic group had fewer UTI recurrences (26% vs. 44% in placebo), and required fewer days of antibiotic therapy overall. These differences did not reach statistical significance, but the trend does seem encouraging, particularly in a population where every recurrence matters.
No serious adverse events were reported. The probiotic was well tolerated, with some minor taste-related complaints. Both groups showed a decrease in hospital days for UTIs over time, suggesting benefit even in placebo likely due to increased monitoring and follow-up.
As the authors note, the trial’s modest sample size limits definitive conclusions, but it adds to the growing signal that targeted probiotic use may reduce infection burden while avoiding the pitfalls of antimicrobial overuse.
For pediatric integrative clinicians, this study supports a tailored, microbiome-conscious strategy in children with recurrent UTIs. While we can’t yet replace antibiotic prophylaxis across the board, this type of probiotic formulation, selected for function, not just genus, may serve as a safe adjunct or alternative in carefully chosen cases.
This is especially relevant for:
As always, probiotic therapy should be layered into a broader plan that includes bladder and bowel optimization, adequate hydration, microbiome-supportive nutrition, and individualized risk assessment. Clinicians should also pay close attention to product sourcing, ensuring strain specificity matches those studied.
While not definitive, this trial reinforces a direction many integrative clinicians are already heading: moving beyond generic probiotics and into precise, strain-based interventions designed with functional outcomes in mind.
For children facing recurrent infections, especially when antibiotics are less appropriate or less effective, this represents a meaningful option.
Want pediatric-focused insights that cut through the noise? Subscribe to my Monday Study Rundown, where I unpack new research and what it means for real-world care.
For more Monday Study Rundowns, click here.
